Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2009 by Nanjing Sike Pharmaceutical Co., Ltd..
Recruitment status was Active, not recruiting

Study NCT00881816 Information provided by Nanjing Sike Pharmaceutical Co., Ltd.

First Received on April 14, 2009. No Changes Posted

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Carcinoma
Stomach Neoplasms

More general conditions related to this trial

Additional drug interventions recognized in this trial

Capecitabine
Fluorouracil
Paclitaxel

More general drug interventions related to this trial

Sponsors listed in this trial